CAJ | 학술논문

目的：探讨“即查即治”方法对宫颈细胞学为高度鳞状上皮内病变(high-grade squamous intraepithelial le-sion， HSIL)妇女的诊治价值，为临床提供有价值的诊疗手段。方法：收集2010年1月-2013年1月，年龄25～83岁，宫颈细胞学筛查为HSIL的妇女200例，按随机化的方法分为实验组(即查即治)和对照组(传统三阶梯诊断程序方法)。比较两组的宫颈电环切术后并发症发生率及最终病理结果。结果：实验组与对照组在宫颈电环切术后并发症发生率差异无统计学意义(P＞0.05)。实验组宫颈上皮内瘤样病变(cervical intraepithelial neoplasia，CIN)病理符合率98%(98/100)，对照组为97%(97/100)，以病理结果≤CIN 1作为过度治疗评判标准，实验组和对照组过度治疗率分别为9%(9/100)、11%(11/100)，两组病理结果及过度治疗率差异无统计学意义(P＞0.05)。结论：“即查即治”策略处理宫颈细胞学为HSIL是安全、经济和有效的诊疗手段。
목적：탐토“즉사즉치”방법대궁경세포학위고도린상상피내병변(high-grade squamous intraepithelial le-sion， HSIL)부녀적진치개치，위림상제공유개치적진료수단。방법：수집2010년1월-2013년1월，년령25～83세，궁경세포학사사위HSIL적부녀200례，안수궤화적방법분위실험조(즉사즉치)화대조조(전통삼계제진단정서방법)。비교량조적궁경전배절술후병발증발생솔급최종병리결과。결과：실험조여대조조재궁경전배절술후병발증발생솔차이무통계학의의(P＞0.05)。실험조궁경상피내류양병변(cervical intraepithelial neoplasia，CIN)병리부합솔98%(98/100)，대조조위97%(97/100)，이병리결과≤CIN 1작위과도치료평판표준，실험조화대조조과도치료솔분별위9%(9/100)、11%(11/100)，량조병리결과급과도치료솔차이무통계학의의(P＞0.05)。결론：“즉사즉치”책략처리궁경세포학위HSIL시안전、경제화유효적진료수단。
Objective: To investigate the safety and efficacy of see-and-treat strategy in the management of high-grade squamous intraepithelial lesion(HSIL),so that to provide a valuable diagnosis and treatment method for HSIL. Methods: 200 non-pregnant women,aged 22-63 years old, recruited as HSIL from January 2010 to January 2013 were randomized into 2 groups:A see-and-treat strategy group,B traditional method of three steps group. The therapeutic efficacy and over-treatment rate of 2 groups were evaluated and compared. Results: There was no significant difference in postoperative complications in the LEEP and colposcopy score between two groups (P>0.05). Histological diagnosis of cervical intraepithelial neoplasia(CIN) was confirmed in 98%(98/100) patients in see & treat group and 97%(97/100) in control group (P>0.05). Using histological diagnosis≤CIN 1 as overtreatment, the overtreatment rate was 9%(9/100) and 11%(11/100) in “see-and-treat” group and control group respectively (P>0.05). Conclusion:See-and-treat strategy is a safe,effective and economical method for the diagnosis and management of HSIL.